Asieris Pharmaceuticals and ReviR Therapeutics Announce Collaboration to Develop AI+RNA-Based Innovative Cancer Therapies

ShanghaiFebruary 8, 2023PR Newswire -- Asieris (Stock Code: 688176.SH), a global innovative pharmaceutical company focusing on urological and gynecological oncology, announced today a collaboration with ReviR Therapeutics ("ReviR"), a biotechnology company dedicated to developing small molecule drugs targeting RNA for cancer and genetic diseases. The partnership will leverage ReviR's self-developed AI drug discovery platform and RNA-targeting technology to jointly advance the research of innovative therapies for urological and gynecological cancers and related major diseases.

The collaboration involves multiple oncology targets, with the aim of improving patient outcomes and advancing the treatment of related diseases through joint efforts. According to the cooperation agreement, Asieris will leverage ReviR's innovative RNA modulation technologies, BindeR and SpliceR, to identify and develop novel therapies targeting RNA for cancer treatment.

As an innovative biotechnology company, ReviR Therapeutics combines AI computing with high-throughput drug discovery technology to provide patients with a new generation of innovative therapeutic drugs. Leveraging its VoyageR AI drug discovery platform, ReviR empowers traditional pharmaceutical methods through computational approaches, advancing solutions to previously undruggable challenges at the RNA level. Currently, its key R&D focus areas include the central nervous system, oncology, and other genetic diseases.

Dr. Paul August, Chief Scientific Officer of ReviR, stated, "Asieris is an international leader in the field of genitourinary oncology therapies, and we are very excited to collaborate with Asieris to develop new therapies and achieve breakthroughs for cancer indications. ReviR's BindeR and SpliceR platforms offer unique advantages in advancing the development of therapies for undruggable cancer targets, and we believe this collaboration will accelerate the progress of novel treatments."

Dr. Peng Yue, CEO of ReviR, stated, "This collaboration with Asieris will bring more extensive expertise, technology, and resources to ReviR, rapidly validating the effectiveness of our small molecule drug discovery platform targeting RNA. More importantly, the collaboration offers the ReviR team an opportunity to synergize with Asieris’ experienced and professional expert team. The combination of these two strong teams will undoubtedly drive innovation and greater breakthroughs in the field of RNA-targeting and small molecule drug development. As the first of many upcoming collaborations for ReviR, we believe this partnership will significantly enhance our ability to improve patient outcomes and propel us into broader areas of oncology research."

Dr. Yu Chen, Vice President of Biology Research in the New Drug Discovery Department and Head of Translational Medicine Research at Asieris, stated: "We are very pleased to collaborate with ReviR Therapeutics, an innovative biotechnology company focused on the development of small molecule therapies targeting RNA. We believe that our expertise in small molecule oncology drug research and development, combined with ReviR's innovative RNA modulation technology, will benefit more patients sooner. We will continue to maintain a differentiated R&D strategy, focusing on tumors and related diseases of the urological and reproductive systems, expanding our innovative influence globally, and providing innovative drugs for patients in China and around the world."

AboutReviR Therapeutics(ReviR Therapeutics)

ReviR Therapeutics (ReviR Therapeutics, Inc.) is an emerging biopharmaceutical company focused on the research and development of small molecule drugs targeting RNA for cancer and genetic diseases. Established in 2021, the company has dual headquarters in California, USA, and Shenzhen, China. Its core team members have deep expertise in computational biology, AI, RNA biology, and drug discovery. Leveraging its cutting-edge technology and AI-powered drug discovery platform VoyageR, the team conducts research on RNA-targeted therapies to develop more effective and safer disease-modifying treatments. ReviR is currently focusing on modulating RNA function through three key mechanisms—BindeR, SpliceR, and DegradeR—to target RNA, tackling "undruggable" targets and addressing unmet clinical needs in oncology and genetic disorders. For more information, please visitwww.revirtx.comOr toinfo@revirtx.comSend an email for consultation.

About Asieris

Asieris (Stock Code: 688176.SH), established in March 2010, is a global innovative pharmaceutical company dedicated to the field of urological and reproductive system cancers as well as other major diseases. Committed to the corporate mission of "Improving human health and enabling a more dignified life," Asieris aims to become an internationally leading pharmaceutical enterprise integrating research, production, and commercialization within its focused therapeutic areas, providing the best integrated diagnosis and treatment solutions for patients in China and worldwide.

Asieris is committed to innovation-driven technologies and products as its core driving force. By building proprietary R&D platforms and core technologies, the company delves deeply into drug mechanisms of action and efficiently screens and evaluates drug candidates. With a well-established internal R&D system and global drug development expertise, Asieris Pharmaceuticals aims to introduce First-in-Class drugs and other innovative treatments addressing significant unmet medical needs in its focused therapeutic areas.

At the same time, Asieris, through independent research and development as well as strategic cooperation, has deeply laid out its product pipeline around urological and reproductive system diseases. It pays close attention to the technological frontier and treatment development trends in this field, gaining insights into and uncovering unmet clinical needs. With forward-looking product planning and lifecycle management, it is building a competitive product portfolio that covers disease diagnosis to treatment, thereby benefiting more patients in China and globally. For more information, please visit www.asieris.cn.